We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Dentists Identify Breast Cancer from Saliva Proteins

By Labmedica staff writers
Posted on 23 Jan 2008
Protein markers in saliva can distinguish women with breast cancer from those with benign tumors and those with healthy cells. More...
These findings potentially could enable dentists and physicians to detect breast cancer during routine office visits.

A study was performed to determine whether protein byproducts secondary to cancer- related oncogenes appear in the saliva of breast cancer patients. Dr. Charles Streckfus, professor of diagnostic sciences at the University of Texas (UT) Health Science Center (Houston, TX, USA) and colleagues analyzed saliva samples from 30 women--10 with benign tumors, 10 with malignant tumors, and 10 without tumors. They found 49 proteins that differentiated between the women with tumors and those without. In a previous study, Prof. Streckfus identified 85% of malignancies with one differing breast cancer protein; a rate he estimated could approach 95% if additional proteins were analyzed.

In this study, with additional analysis, the scientists were able to distinguish between benign and malignant tumors. According to Prof. Streckfus, the extra analysis could help eliminate false-positive results and allow doctors to determine the next treatment options for women with breast cancer.

A large, multicenter trial is planned in about two years at the UT M.D. Anderson Cancer Center (Houston, Texas, USA) and the UT Dental Branch (Houston, Texas, USA). The proposed test will be conducted on a gold-plated chip or lab dish. A laser will then be used to distinguish protein markers in saliva applied to the chip. Such a test would be used in conjunction with other tools, including mammograms. There are currently no blood tests available for detecting breast cancer.

"This will be a noninvasive, quick means of detection,” Prof. Streckfus said about the new test. "With it, dentists will be able to catch cancers before a woman can feel a lump.”

Prof. Streckfus noted that the test could be useful for breast cancer survivors who need to be monitored regularly and also in developing countries that lack mammography technology.


Related Links:
University of Texas Health Science Center
M.D. Anderson Cancer Center
University of Texas Dental Branch

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.